News Regulated Transparency/Denominator Information on the Total Number of Voting Rights (Denominator) following conversion notices from NEGMA EN NL December 30, 2021
News Regulated Transparency/Denominator Information on the Total Number of Voting Rights (Denominator) following conversion notices from NEGMA EN NL November 30, 2021
General News Regulated OXURION NV Secures EUR 10 Million Convertible Bond Financing from Kreos Capital and Pontifax Ventures EN November 22, 2021
General News First Patient Dosed in Part B of Phase 2 KALAHARI Study Evaluating Multiple Administrations of THR-149 versus aflibercept for Treatment of Diabetic Macular Edema (DME) EN November 15, 2021
General News Oxurion NV Announces Initiation of Equity Analyst Coverage by H.C. Wainwright with a “Buy” Recommendation EN November 4, 2021
News Regulated Transparency/Denominator Information on the Total Number of Voting Rights (Denominator) following conversion notices NEGMA EN NL November 3, 2021
General News Oxurion NV Announces First Patient Dosed in its Phase 2 Study Evaluating THR-687 for the treatment of Diabetic Macular Edema (DME) EN October 13, 2021
General News Positive Phase 2 Part A THR-149 data shared at the America Society of Retina Specialists (ASRS) Annual Scientific Meeting EN October 11, 2021
General News OXURION to Present at the Lytham Partners Fall 2021 Investor Conference EN October 5, 2021
General News Regulated OXURION Announces Positive Results from Part A of Phase 2 Study Evaluating THR-149 for Treatment of Diabetic Macular Edema (DME) EN September 30, 2021
General News OXURION to Present Clinical and Pre-Clinical Data at Upcoming EURETINA 2021 Virtual Congress EN September 8, 2021
General News Oxurion NV – Publication of Positive Phase 1 Clinical Data evaluating THR-687 for Treatment of DME in Ophthalmology Science, the American Academy of Ophthalmology Journal EN August 17, 2021
General News Oxurion NV – Journal of Pharmacokinetics and Pharmacodynamics highlights desirable PK/PD profiles of THR-687 and THR-149 EN August 16, 2021
General News OXURION Confirms Institutional Review Board Approval and Submission of the Investigational New Drug Application to the FDA to Start Phase 2 Study Evaluating THR-687 for Diabetic Macular Edema (DME) EN June 10, 2021
General News OXURION Completes Patient Enrollment for Part A of Phase 2 Study Evaluating THR-149 for Treatment of Diabetic Macular Edema (DME) EN June 8, 2021
